Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test

Stock Information for Biomerica Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biomerica Inc.

Biomerica Reports Second Quarter Fiscal 2026 Financial Results
Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio
Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.
Biomerica Reports First Quarter Fiscal 2026 Financial Results
Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors
Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.